Breast Cancer | Specialty

Dr. Sparano on Improving Liquid Biopsies in Breast Cancer

January 30th 2019

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses ways to improve the clinical utility of liquid biopsies in the treatment of patients with breast cancer.

Hamilton Highlights Single-Agent Abemaciclib Data in HR+/HER2- Breast Cancer

January 28th 2019

Erika P. Hamilton, MD, discusses the findings from the phase II nextMONARCH 1 study of abemaciclib in HR-positive, HER2-negative advanced breast cancer.

Extended Adjuvant Therapy in Breast Cancer Requires Individualized Approach

January 26th 2019

Paula Klein, MD, discusses the research surrounding extended adjuvant therapy in early-stage hormone receptor-positive breast cancer.

SABCS 2018 Showcased Practice-Changing Advances in Breast Cancer

January 25th 2019

Stephen C. Malamud, MD, reflects on the intriguing and practice-changing data presented at the 2018 SABCS.

TNBC Pipeline Bursting With Effective Agents

January 24th 2019

Meghna Trivedi, MD, highlights 3 classes of agents that are showing promise in patients with metastatic triple-negative breast cancer.

Dr. Goetz on Survival Data With CDK4/6 Inhibitors in Breast Cancer

January 23rd 2019

Matthew P. Goetz, MD, chair of the Breast Cancer Disease-Oriented Group and co-leader of the Women’s Cancer Center at the Mayo Clinic, discusses survival data with CDK4/6 inhibitors in patients with hormone receptor-positive breast cancer.

FDA Issues Complete Response Letter for Sacituzumab Govitecan in TNBC

January 18th 2019

The FDA has issued a complete response letter to Immunomedics regarding its biologics license application for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies, citing chemistry, manufacturing, and control matters.

FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices

January 18th 2019

The FDA has issued a letter to healthcare providers that they should monitor patients with a type of peripheral arterial disease who have been treated with vascular balloons that were coated with paclitaxel or stents that release paclitaxel in the femoropopliteal artery in the leg.

Dr. Shao on Managing Toxicity With Neratinib in HER2+ Breast Cancer

January 16th 2019

Theresa Shao, MD, assistant professor of medicine, hematology and medical oncology, Icahn School of Medicine, Mount Sinai Medical Center, discusses managing toxicities associated with neratinib (Nerlynx) in patients with HER2-positive breast cancer.

Chemoimmunotherapy in TNBC: The KEYNOTE-355 Trial

January 15th 2019

Questioning CDK4/6 Inhibitor Cross-Resistance in HR+ mBC

January 15th 2019

Antibody-Drug Conjugates in TNBC: Sacituzumab Govitecan

January 15th 2019

Combining PARP and Checkpoint Inhibitors in TNBC

January 15th 2019

Chemoimmunotherapy in TNBC: The IMpassion130 Trial

January 15th 2019

Moving CDK4/6 Inhibition to HER2+ Breast Cancer

January 15th 2019

HER2+ Breast Cancer: Neratinibs Role as Adjuvant Therapy

January 15th 2019

Making Sense of Adjuvant Therapy in HER2+ Breast Cancer

January 15th 2019

HR+ Metastatic Breast Cancer: Upfront CDK4/6 Inhibition

January 15th 2019

Current State of CDK4/6 Inhibition in HR+ mBC

January 15th 2019

Pathologic Complete Response in HER2+ Breast Cancer

January 15th 2019